Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network
2022 Translational Cancer Research. All rights reserved..
Background: Pancreatic cancer is an insidious and heterogeneous malignancy with poor prognosis that is often locally unresectable. Therefore, determining the underlying mechanisms and effective prognostic indicators of pancreatic cancer may help optimize clinical management. This study was conducted to develop a prognostic model for pancreatic cancer based on a competing endogenous RNA (ceRNA) network.
Methods: We obtained transcriptomic data and corresponding clinicopathological information of pancreatic cancer samples from The Cancer Genome Atlas (TCGA) database (training set). Based on the ceRNA interaction network, we screened candidate genes to build prediction models. Univariate Cox regression analysis was performed to screen for genes associated with prognosis, and least absolute shrinkage and selection operator (LASSO) regression analysis was conducted to construct a predictive model. A receiver operating characteristic (ROC) curve was drawn, and the C-index was calculated to evaluate the accuracy of the prediction model. Furthermore, we downloaded transcriptomic data and related clinical information of pancreatic cancer samples from the Gene Expression Omnibus database (validation set) to evaluate the robustness of our prediction model.
Results: Eight genes (ANLN, FHDC1, LY6D, SMAD6, ACKR4, RAB27B, AUNIP, and GPRIN3) were used to construct the prediction model, which was confirmed as an independent predictor for evaluating the prognosis of patients with pancreatic cancer through univariate and multivariate Cox regression analysis. By plotting the decision curve, we found that the risk score model is an independent predictor has the greatest impact on survival compared to pathological stage and targeted molecular therapy.
Conclusions: An eight-gene prediction model was constructed for effectively and independently predicting the prognosis of patients with pancreatic cancer. These eight genes identified show potential as diagnostic and therapeutic targets.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Translational cancer research - 11(2022), 11 vom: 15. Nov., Seite 4019-4036 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qu, Yuanxu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Competing endogenous RNA network (ceRNA network) |
|---|
| Anmerkungen: |
Date Revised 22.12.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/tcr-22-709 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350352437 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350352437 | ||
| 003 | DE-627 | ||
| 005 | 20231226044813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/tcr-22-709 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350352437 | ||
| 035 | |a (NLM)36523322 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qu, Yuanxu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2022 Translational Cancer Research. All rights reserved. | ||
| 520 | |a Background: Pancreatic cancer is an insidious and heterogeneous malignancy with poor prognosis that is often locally unresectable. Therefore, determining the underlying mechanisms and effective prognostic indicators of pancreatic cancer may help optimize clinical management. This study was conducted to develop a prognostic model for pancreatic cancer based on a competing endogenous RNA (ceRNA) network | ||
| 520 | |a Methods: We obtained transcriptomic data and corresponding clinicopathological information of pancreatic cancer samples from The Cancer Genome Atlas (TCGA) database (training set). Based on the ceRNA interaction network, we screened candidate genes to build prediction models. Univariate Cox regression analysis was performed to screen for genes associated with prognosis, and least absolute shrinkage and selection operator (LASSO) regression analysis was conducted to construct a predictive model. A receiver operating characteristic (ROC) curve was drawn, and the C-index was calculated to evaluate the accuracy of the prediction model. Furthermore, we downloaded transcriptomic data and related clinical information of pancreatic cancer samples from the Gene Expression Omnibus database (validation set) to evaluate the robustness of our prediction model | ||
| 520 | |a Results: Eight genes (ANLN, FHDC1, LY6D, SMAD6, ACKR4, RAB27B, AUNIP, and GPRIN3) were used to construct the prediction model, which was confirmed as an independent predictor for evaluating the prognosis of patients with pancreatic cancer through univariate and multivariate Cox regression analysis. By plotting the decision curve, we found that the risk score model is an independent predictor has the greatest impact on survival compared to pathological stage and targeted molecular therapy | ||
| 520 | |a Conclusions: An eight-gene prediction model was constructed for effectively and independently predicting the prognosis of patients with pancreatic cancer. These eight genes identified show potential as diagnostic and therapeutic targets | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Pancreatic cancer | |
| 650 | 4 | |a competing endogenous RNA network (ceRNA network) | |
| 650 | 4 | |a computational biology | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a survival analysis | |
| 700 | 1 | |a Lu, Jiongdi |e verfasserin |4 aut | |
| 700 | 1 | |a Mei, Wentong |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Yuchen |e verfasserin |4 aut | |
| 700 | 1 | |a Bian, Chunjing |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Yixuan |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yulin |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Fei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational cancer research |d 2012 |g 11(2022), 11 vom: 15. Nov., Seite 4019-4036 |w (DE-627)NLM219999724 |x 2219-6803 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:11 |g day:15 |g month:11 |g pages:4019-4036 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/tcr-22-709 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 11 |b 15 |c 11 |h 4019-4036 | ||